Femasys inc. obtains medical device establishment license from health canada

Atlanta, aug. 31, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative diagnostic products constituting a broad portfolio of in-office accessible solutions, today announced that it has obtained a medical device establishment license (“mdel”) from health canada (license number 24825). the mdel license is issued by health canada's regulatory operations and enforcement branch (roeb) to companies for the activities of manufacturing, importing and distributing and selling of medical devices for human use in canada. this license allows femasys to directly sell its four products, femaseed®, femvue®, femcath® and femcerv®, approved in canada.
FEMY Ratings Summary
FEMY Quant Ranking